Revenue rises, adjusted EBITDA loss improves for Avacta : vi

Oncology-focussed drugs and diagnostics developer Avacta reported full-year revenue of £9.7m in its preliminary results on Tuesday, up from £2.9m year-on-year.

Related Keywords

United States , American , Christina Coughlin , Alastair Smith , American Association For Cancer Research , Avacta Group , Cytoimmune Therapeutics , Cancer Research , Launch Diagnostics , Avacta Diagnostics , United Kingdom , Revenue , Crises , , Adjusted , Ebitda , Loss , Improves , Avacta , Category All , Category Market Report , Category Company News , Category News And Announcements , Category Aim Bulletin , Category Tecnologia , Category Market Pulse , Category Sectorial Health Technology , Mostread Technology ,